A Study of Pharmacogenomics Results and Clinical Data of Patients with Chronic Myeloid Leukemia and Lung Cancer to Assess Current and Future Therapeutic Relevance

Overview

About this study

The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing for a group of patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • A Mayo Clinic patient with either CML or lung cancer within the divisions of hematology and oncology, divisions piloting PGx testing with the Center for Individualized Medicine, seeking clinical information from emerging PGx testing technologies available in CLIA/CAP laboratories
  • Patient age 18 or above
  • Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures
  • Patient is willing to engage in a medication assessment as part of their clinical visit preparation (when needed)

Exclusion Criteria

  • Patient with uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Mrinal Patnaik, M.B.B.S.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions